| 2025-06-20 10:16 | CC:NRX | Nurexone Biologic Inc | 0.67 | News Release200 | Nurexone Biologic joins HealthTech Hub program |
| 2025-06-04 19:38 | CC:NRX | Nurexone Biologic Inc | 0.71 | News Release200 | Nurexone presents at conference, to hold AGM June 18 |
| 2025-05-30 18:01 | CC:NRX | Biologic Inc | 0.68 | News Release200 | Nurexone Biologic adviser to present at ASIA meeting |
| 2025-05-27 08:59 | CC:NRX | NurExone Biologic Inc. | 0.66 | News Release200 | NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-05-27 08:42 | CC:NRX | Nurexone Biologic Inc | 0.66 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2025-05-27 08:42 | CC:NRX | Nurexone Biologic Inc | 0.66 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2025-05-09 03:27 | CC:NRX | Nurexone Biologic Inc | 0.66 | News Release200 | Nurexone's ExoPTEN data presented at annual meeting |
| 2025-05-02 16:05 | CC:NRX | NurExone Biologic Inc. | 0.705 | News Release200 | NurExone Expands European Engagement with Investor Events in Germany and Switzerland |
| 2025-04-24 16:55 | CC:NRX | Nurexone Biologic Inc | 0.64 | Private Placement250 | Nurexone Biologic 3,543,238-share private placement |
| 2025-04-24 16:15 | CC:NRX | NurExone Biologic Inc. | 0.64 | News Release200 | NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025 |
| 2025-04-22 20:18 | CC:NRX | Nurexone Biologic Inc | 0.65 | News Release200 | Nurexone appoints Licht as CEO of Exo-Top |
| 2025-04-09 17:16 | CC:NRX | Nurexone Biologic Inc | 0.68 | SEDAR MD & A815 | SEDAR MD & A |
| 2025-04-09 17:15 | CC:NRX | NurExone Biologic Inc. | 0.68 | News Release200 | NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update |
| 2025-04-09 17:04 | CC:NRX | Nurexone Biologic Inc | 0.68 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2025-04-04 16:12 | CC:NRX | Nurexone Biologic Inc | 0.67 | News Release200 | Nurexone closes $2.3-million private placement |
| 2025-03-14 16:42 | CC:NRX | Nurexone Biologic Inc | 0.65 | News Release200 | Nurexone completes preclinical study for ExoPTEN |
| 2025-02-27 16:03 | CC:NRX | NurExone Biologic Inc. | 0.57 | News Release200 | NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award |
| 2025-02-14 16:03 | CC:NRX | NurExone Biologic Inc. | 0.61 | News Release200 | NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation |
| 2025-02-05 18:29 | CC:NRX | Nurexone Biologic Inc | 0.58 | News Release200 | Nurexone Biologic forms U.S.-based subsidiary |
| 2025-02-03 17:16 | CC:NRX | Nurexone Biologic Inc | 0.58 | Private Placement250 | Nurexone Biologic 856,996-share private placement |
| 2025-01-21 19:03 | CC:NRX | Nurexone Biologic Inc | 0.62 | News Release200 | Nurexone closes $479,917 private placement |
| 2025-01-08 18:42 | CC:NRX | Nurexone Biologic Inc | 0.63 | News Release200 | Nurexone Biologic acquires master cell bank |
| 2024-12-06 17:31 | CC:NRX | Nurexone Biologic Inc | 0.73 | News Release200 | Nurexone talks up ExoPTEN preclinical results |
| 2024-11-27 07:11 | CC:NRX | Nurexone Biologic Inc | 0.70 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-11-27 07:11 | CC:NRX | Nurexone Biologic Inc | 0.70 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-11-27 07:01 | CC:NRX | NurExone Biologic Inc. | 0.70 | News Release200 | NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 2024-11-13 16:28 | CC:NRX | Nurexone Biologic Inc | 0.63 | News Release200 | Nurexone's ExoPTEN therapy receives EMA orphan status |
| 2024-11-12 19:56 | CC:NRX | Nurexone Biologic Inc | 0.60 | Private Placement250 | Nurexone Biologic 3,159,359-share private placement |
| 2024-11-01 17:04 | CC:NRX | Nurexone Biologic Inc | 0.67 | News Release200 | Nurexone closes final tranche of placement |
| 2024-09-26 18:08 | CC:NRX | Nurexone Biologic Inc | 0.57 | News Release200 | Nurexone closes $1.61M first tranche of financing |
| 2024-09-06 16:48 | CC:NRX | Nurexone Biologic Inc | 0.56 | News Release200 | Nurexone finds one-week window for ExoPTEN use |
| 2024-08-28 19:06 | CC:NRX | Nurexone Biologic Inc | 0.63 | News Release200 | Nurexone spends $510,000 (U.S.) on R&D in Q2 2024 |
| 2024-08-28 14:41 | CC:NRX | Nurexone Biologic Inc | 0.65 | SEDAR Annual Information Form802 | SEDAR Annual Information Form |
| 2024-08-27 17:18 | CC:NRX | Nurexone Biologic Inc | 0.65 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-08-27 17:18 | CC:NRX | Nurexone Biologic Inc | 0.65 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-08-15 17:37 | CC:NRX | Nurexone Biologic Inc | 0.59 | News Release200 | Nurexone talks exosome manufacturing process |
| 2024-08-09 16:19 | CC:NRX | Nurexone Biologic Inc | 0.59 | News Release200 | Nurexone's ExoPTEN shows homing capacity in study |
| 2024-08-01 17:20 | CC:NRX | Nurexone Biologic Inc | 0.64 | News Release200 | Nurexone transfers tech to GMP-compliant vendor |
| 2024-07-29 16:04 | CC:NRX | NurExone Biologic Inc. | 0.61 | News Release200 | NurExone Announces Further Expansion of ExoPTEN Patent Coverage |
| 2024-07-17 19:46 | CC:NRX | Nurexone Biologic Inc | 0.69 | News Release200 | Nurexone receives preliminary results of ExoPTEN study |
| 2024-07-05 08:43 | CC:NRX | NurExone Biologic Inc. | 0.69 | News Release200 | Updates from NurExone: Growth Conference Presentation and Website Relaunch |
| 2024-06-28 16:46 | CC:NRX | Nurexone Biologic Inc | 0.66 | News Release200 | Nurexone's Exopten to go through preclinical study |